Thu, 20 Dec 2012 17:03 GMT Reuters * Cites increase in nonfatal side effects * Says it will not seek U.S. approval of high-profile drug * Failure is latest setback for HDL-raising drugs * Merck shares fall 2.5 percent  (Adds… Read More ›